A5379: B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

This Study is
No Longer Enrolling

Description

A5379 is a study looking at hepatitis B vaccination in adults living with HIV. Hepatitis B is a serious viral infection that affects the liver and is transmitted through blood and body fluids. The study will involve individuals who have received a previous hepatitis B vaccination but the vaccine did not respond well and individuals who have never received the vaccination. The study will take place both in the US and internationally. The study will compare how well an individual responds to the vaccine in different groups based on the type of vaccine and number of doses.

Details
Age

Adult

Eligibility

- Living with HIV - Been on HIV treatment for more than 56 days - Previously received vaccines for hepatitis B, but the vaccines didn’t work - There will be a small group of participants (73) who have never been vaccinated for hepatitis B. - CD4 cell count (the number of white blood cells that fight infection) more than 100 - HIV viral load (how much HIV is in the body) less than 1000 - In the group vaccinated with a hepatitis B vaccine, the vaccination was over 168 days ago - No previous hepatitis B infection or exposure to hepatitis B infection

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital

Study ID

Protocol Number: 19-2935

More information available at ClinicalTrials.gov: NCT04193189

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers